GDC-0570 is a novel, potent, selective, orally active pan- PIM inhibitor. GDC-0570 demonstrates synergistic antitumor efficacy when combined with Sotorasib ( HY-114277 ) in acquired KRASis-resistant NSCLC.
Products | Products > Signaling Pathways > JAK/STAT Signaling | Products > Research Areas > Cancer | Products > Research Areas > Cancer > Cancer Targeted Therapy | Products > Research Areas > Cancer > Cancer Drug Resistance | Products > Research Areas > Cancer > Cancer Metabolism and Metastasis | Products > Signaling Pathways > Pim
感谢您来到爆牛贸易,请为我们留言或者使用以下方式联系我们,我们将尽快给您回复,并为您提供最真诚的服务,谢谢。